Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

Abstract Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an...

Full description

Bibliographic Details
Main Authors: K. Lisenko, G. Dingeldein, M. Cremer, M. Kriegsmann, A. D. Ho, M. Rieger, M. Witzens-Harig
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Primary mediastinal B-cell lymphoma (PMBCL)
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine and prednisone (CHOP)
International prognostic index (IPI)
Online Access:http://link.springer.com/article/10.1186/s12885-017-3332-3

Internet

http://link.springer.com/article/10.1186/s12885-017-3332-3

Similar Items